MedPath
Found 39 clinical trials|View Analysis
Sort by:

The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD

Phase 2
Active, not recruiting
Conditions
Hodgkin's Lymphoma
Interventions
Drug: Bendamustine
Drug: Gemcitabine
Drug: Dexamethasone
Diagnostic Test: PET/CT
Procedure: Autologous Stem Cell Transplant
First Posted Date
2018-08-06
Last Posted Date
2024-04-12
Lead Sponsor
Polish Lymphoma Research Group
Target Recruit Count
115
Registration Number
NCT03615664
Locations
🇵🇱

Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland

🇵🇱

Szpitale Pomorskie Sp. z o.o., Gdynia, Poland

🇵🇱

Oddział Chorób Wewnętrznych i Chemioterapii Onkologicznej, Samodzielny Publiczny Szpital Kliniczny im. A.Mielęckiego, Katowice, Poland

and more 10 locations

OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy

Phase 2
Conditions
Classical Hodgkin Lymphoma
Hodgkin Disease
Hodgkin Lymphoma
Hodgkin Lymphoma (Category)
Interventions
First Posted Date
2018-05-17
Last Posted Date
2019-11-18
Lead Sponsor
King Abdullah International Medical Research Center
Target Recruit Count
220
Registration Number
NCT03527628
Locations
🇸🇦

King Abdulaziz Medical City, Ministry of National Guard, Riyadh, Saudi Arabia

Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

Phase 4
Recruiting
Conditions
Pediatric Hodgkin's Disease
Interventions
Radiation: No radiotherapy if CR at the end of chemotherapy.
Drug: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
Drug: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Drug: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
Drug: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Drug: Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
Drug: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Radiation: IN 30Gy RT in case of PR at the end of chemotherapy
Drug: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
First Posted Date
2018-04-17
Last Posted Date
2024-03-20
Lead Sponsor
Hospital JP Garrahan
Target Recruit Count
500
Registration Number
NCT03500133
Locations
🇦🇷

Hospital JP Garrahan, Buenos Aires, CF, Argentina

FIL Study on ABVD DD-DI As Upfront Therapy in HL.

Phase 3
Completed
Conditions
Hodgkin Lymphoma
Interventions
First Posted Date
2017-05-19
Last Posted Date
2024-12-31
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Target Recruit Count
500
Registration Number
NCT03159897
Locations
🇮🇹

Ospedale Madonna delle Grazie - Ematologia, Matera, Italy

🇮🇹

Presidio ospedaliero "A. TORTORA", Pagani, Italy

🇮🇹

Istituto Clinico Humanitas - U.O. Ematologia, Rozzano (MI), Italy

and more 43 locations

Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol

Not Applicable
Conditions
Advanced Hodgkin's Lymphoma
Interventions
Drug: ABVD
Drug: Natulan
First Posted Date
2016-06-15
Last Posted Date
2018-09-04
Lead Sponsor
Lee's Pharmaceutical Limited
Target Recruit Count
92
Registration Number
NCT02800447

Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma

Phase 4
Conditions
Lymphoma, Non-Hodgkin;Hodgkin Disease
Interventions
Drug: R-CHOP/CHOPE or ABVD chemotherapy regimen
Drug: R-CDOP/CDOPE or DBVD chemotherapy regimen
First Posted Date
2015-08-18
Last Posted Date
2019-04-02
Lead Sponsor
Shandong Provincial Hospital
Target Recruit Count
360
Registration Number
NCT02526823
Locations
🇨🇳

Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

First Posted Date
2014-11-21
Last Posted Date
2021-07-26
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
40
Registration Number
NCT02298283
Locations
🇫🇷

CH Sud Francilien, Corbeil-Essonnes, France

🇫🇷

Hôpital André Mignot, Le Chesnay, France

🇫🇷

Centre Léon Bérard, Lyon, France

and more 27 locations

Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma

Phase 2
Conditions
Hodgkin Lymphoma
Interventions
First Posted Date
2014-10-27
Last Posted Date
2014-10-27
Lead Sponsor
University of Modena and Reggio Emilia
Target Recruit Count
12
Registration Number
NCT02275598
Locations
🇮🇹

Hematology, Azienda Ospedaliera Arcispedale S.Maria Nuova IRCCS, Reggio Emilia, Italy

🇮🇹

Institute of Hematology and Medical Oncology "L. e A. Seràgnoli" at the University of Bologna, Bologna, Italy

🇮🇹

Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy

Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Hodgkin Lymphoma
Interventions
Drug: dose dense ABVD
First Posted Date
2014-09-25
Last Posted Date
2018-02-09
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Target Recruit Count
100
Registration Number
NCT02247869
Locations
🇮🇹

Oncologia Medica A Centro di Riferimento Oncologico, Aviano, Pordenone, Italy

🇮🇹

U.O. Oncoematologia Ospedale "Andrea Tortora", Pagani, Salerno, Italy

🇮🇹

UO Ematologia Ospedale San Donato, Arezzo, Italy

and more 34 locations

Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)

Phase 3
Withdrawn
Conditions
Hodgkin Lymphoma
Interventions
Drug: ABVD + FDG-PET/CT Scan treatment adaptation
Drug: BEACOPPesc
First Posted Date
2012-07-30
Last Posted Date
2021-02-15
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Registration Number
NCT01652261
Locations
🇩🇰

Rigshospitalet, Copenhagen, Denmark

© Copyright 2025. All Rights Reserved by MedPath